Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Chief Commercial Officer | November 22, 2023 | November 27, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date November 22, 2023 · Filed November 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 83,342 |
Reported balance
After 2023-11-22 transaction · row 1
1 source rowRow 1 · 2023-11-22 · Sale · Disposed 3,464 · Balance 83,342 F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 22, 2023 Filed Nov 27, 2023 23:18 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,464 | $43.34 | $150,118.33 |
DisclosureSEC source: 0001610717-23-000367 · form4.xml · nonDerivative · entry 1 Wilbur James · CIK 0001940931 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,342 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 21:30 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 14,718 | $42.09 | $619,493.87 |
DisclosureSEC source: 0001610717-23-000361 · form4.xml · nonDerivative · entry 1 Wilbur James · CIK 0001940931 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,806 F1 · price: This transaction was executed in multiple trades at prices ranging from $42.05 to $42.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2 · balance_after: Includes 271 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 14, 2023. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 21:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 9,699 | $45.78 | $444,030.89 |
DisclosureSEC source: 0001610717-23-000236 · form4.xml · nonDerivative · entry 1 Wilbur James · CIK 0001940931 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,253 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 23, 2023 Filed May 25, 2023 21:49 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 316 | $55.07 | $17,400.63 |
DisclosureSEC source: 0001610717-23-000065 · form4.xml · nonDerivative · entry 1 Wilbur James · CIK 0001940931 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,952 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes 874 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 12, 2023. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 22:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantPerformance-based Restricted Stock Units · Derivative | 7,278 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-013503 · form4.xml · derivative · entry 3 Wilbur James · CIK 0001940931 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,278 Underlying: Class A Common Stock · 7,278 shares Expires 2028-04-01 F3 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/3rd of the PSUs shall vest upon the Issuer's Class A Common Stock achieving each of three escalating stock price milestones, subject to the Reporting Person continuing as a service provider through each such date. F3 · derivative.exercise_date: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/3rd of the PSUs shall vest upon the Issuer's Class A Common Stock achieving each of three escalating stock price milestones, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 22:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 14,555 | $0.00 Strike: $50.10 | $0.00 |
DisclosureSEC source: 0001140361-23-013503 · form4.xml · derivative · entry 2 Wilbur James · CIK 0001940931 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,555 Underlying: Class A Common Stock · 14,555 shares Expires 2033-03-21 F2 · derivative.exercise_date: 1/48th of the total number of shares subject to the option vest on each monthly anniversary measured from April 1, 2023, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 22:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 14,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-013503 · form4.xml · nonDerivative · entry 1 Wilbur James · CIK 0001940931 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,394 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/16th of the RSUs shall vest on each quarterly anniversary measured from February 21, 2023, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 21:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 239,596 | $0.00 Strike: $33.67 | $0.00 |
DisclosureSEC source: 0001567619-22-017561 · doc1.xml · derivative · entry 2 Wilbur James · CIK 0001940931 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,596 Underlying: Class A Common Stock · 239,596 shares Expires 2032-09-14 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the one-year anniversary measured from July 27, 2022, and 1/48th of the shares vest monthly thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 21:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 95,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-017561 · doc1.xml · nonDerivative · entry 1 Wilbur James · CIK 0001940931 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,839 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 25% of the RSUs vest on the one-year anniversary measured from August 21, 2022, and 1/16th of the RSUs vest quarterly thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.